Is Dilactone actinomycindioic D acid Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Dilactone actinomycindioic D acid? Is Dilactone actinomycindioic D acid safe for nursing mother and child? Does Dilactone actinomycindioic D acid extracts into breast milk? Does Dilactone actinomycindioic D acid has any long term or short term side effects on infants? Can Dilactone actinomycindioic D acid influence milk supply or can Dilactone actinomycindioic D acid decrease milk supply in lactating mothers?
Dilactone actinomycindioic D acid lactation summary
- DrLact safety Score for Dilactone actinomycindioic D acid is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Dilactone actinomycindioic D acid may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Dilactone actinomycindioic D acid may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Dilactone actinomycindioic D acid .
- Usage of Dilactone actinomycindioic D acid is in contradiction to breastfeeding hence if it is must to use Dilactone actinomycindioic D acid and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Dilactone actinomycindioic D acid usage in lactation
Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 10 days of pumping-and-dumping.
Answer by DrLact: About Dilactone actinomycindioic D acid usage in lactation
No information is available on the use of Dilactone actinomycindioic D acid during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during Dilactone actinomycindioic D acid therapy and for 14 days after the last dose.
Alternate Drugs
Dactinomycin(Dangerous)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Erlotinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Letrozole(Dangerous)
Imatinib(Unsafe)
Exemestane(Dangerous)
Dasatinib(Unsafe)
Azelaic Acid(Safe)
Dactinomycin(Dangerous)
Nilotinib(Unsafe)
Vincristine(Dangerous)
Ipilimumab(Unsafe)
Tamoxifen(Dangerous)
Cetuximab(Unsafe)
Mitoxantrone(Dangerous)
Carboplatin(Dangerous)
Mercaptopurine(Safe)
Paclitaxel(Dangerous)
Gemcitabine(Dangerous)
Fluorouracil(Dangerous)
Nivolumab(Unsafe)
Hydroxyurea(Low Risk)
Alemtuzumab(Low Risk)
Vinblastine(Dangerous)
Etoposide(Dangerous)
Docetaxel(Dangerous)
Rituximab(Low Risk)
Pazopanib(Unsafe)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Vinorelbine(Dangerous)
Cyclophosphamide(Dangerous)
Bevacizumab(Low Risk)
Dacarbazine(Dangerous)
Cisplatin(Unsafe)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Dactinomycin(Dangerous)
Dactinomycin(Dangerous)
Fusidic Acid(Safe)